Dr. Tanioka on the Results of CALGB 40601 in HER2+ Breast Cancer

Video

In Partnership With:

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.

This study was an integrated analysis of multidimensional genomic data that explored neoadjuvant weekly paclitaxel and trastuzumab (Herceptin) with or without lapatinib (Tykerb).

Results showed that tumor genetics, RNA subtype, and the microenvironment were independently predictive of response to trastuzumab-containing therapies. According to Tanioka, these results support integrating RNA- and DNA-based tumor assessments to determine response to HER2-targeting.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "